14″ January “2022” XIGASHO: AL JAZEERA
Ururka Caafimaadka Adduunka (WHO) ayaa laba dawo oo kale ku daray hab-raacyadeeda daawaynta lagu taliyey ee COVID-19, maadaama kala duwanaanshaha Omicron ee faafa ee coronavirus uu kiciyo qalliin aan hore loo arag oo adduunka oo dhan ah.
Daawada baricitinib, oo sidoo kale loo isticmaalo daawaynta rheumatoid arthritis-ka, ayaa “si adag loogu talinayaa” bukaanada qaba COVID-19 daran ama daran, oo ay weheliso corticosteroids, guddiga khubarada caalamiga ah ee hay’adda Qaramada Midoobay ayaa ku sheegay tilmaamaha ay daabacday Ingiriiska. Joornaalka Caafimaadka Jimcaha.
Daawadu waxay yaraynaysaa baahida hawo-mareenka waxaana la ogaaday inay wanaajiso fursadaha badbaadada bukaanada iyada oo aan lahayn calaamad muujinaysa koror falcelin xun, guddigu wuxuu yidhi.
Guddigu waxa kale oo ay siiyeen “talobixin shuruudeed” sotrovimab, tijaabo ah daawaynta ka hortagga unugyada monoclonal, ee kuwa aan daran COVID-19 laakiin khatarta ugu badan ugu jira in isbitaal la dhigo. Unugyada difaaca jirka ee monoclonal waa shaybaar-abuuray xeryahooda oo u ekaysiiya habka difaaca dabiiciga ah ee jidhka.
Talooyinka daawaynta cusub ayaa imanaya iyada oo masiibada faafa ay sii kordhisay adduunka oo dhan. In ka badan 15 milyan oo kiis oo cusub oo COVID-19 ah ayaa lagu soo warramey WHO usbuucii la soo dhaafay – ilaa hadda inta ugu badan hal toddobaad gudaheed – oo uu wado nooca Omicron, kaasoo beddelaya kala duwanaanshaha Delta ku dhawaad meel kasta.
Talooyinka ayaa lagu saleeyay caddaymo cusub oo laga helay toddoba tijaabo oo ay ku lug lahaayeen in ka badan 4,000 bukaan oo qaba xaalado aan daran, daran, iyo xaalado halis ah oo COVID-19 ah.
“Hagitaanku wuxuu ku darayaa talooyinka hore ee isticmaalka interleukin-6 receptor blockers iyo corticosteroids systemic ee bukaanada qaba covid-19 daran ama daran; talooyinka shuruudaha ah ee isticmaalka casirivimab-imdevimab (daawaynta kale ee monoclonal antibody) ee bukaannada la doortay; iyo ka soo horjeeda isticmaalka convalescent plasma, ivermectin iyo hydroxychloroquine ee bukaanada qaba covid-19 iyada oo aan loo eegin darnaanta cudurka,” WHO ayaa ku tiri hadal ay soo saartay.
Hay’adda samafalka ee Médecins Sans Frontières (MSF) ayaa soo dhaweysay talooyinka cusub waxayna ku boorisay dowladaha inay wax ka qabtaan ilaalinta patent-ka si loo hubiyo in inta ugu badan ee dadka ay awoodaan inay ka faa’iideystaan daawaynta.
Baricitinib waxaa soo saaray shirkadda weyn ee dawooyinka ee Maraykanka Eli Lilly, iyo in kasta oo noocyada guud laga heli karo Hindiya iyo Bangladesh, shatiyada ayaa laga dhaqangeliyaa dalal kale oo badan oo ay ku jiraan Brazil iyo Indonesia.
犀利士 “Ku dhawaad laba sano, waxaan si taxadar la’aan ah u aragnay dad u dhimanaya COVID-19 iyada oo ay jiraan mowjado cudur oo masiibo ah. Waddamada ay MSF ka shaqeyso,” Dr Márcioda Fonseca, oo ah lataliyaha caafimaadka cudurrada faafa ee Ololaha Helitaanka MSF, ayaa bayaan ku yiri.
“Suruurtagalnimada bixinta daryeelka degdegga ah ee heerka sare ah waa xaddidan yihiin, sidaa darteed badbaadinta nolosha dad badan oo qaba caabuqyada daran iyo kuwa halista ah waxay si weyn ugu tiirsan tahay helitaanka dawooyin la awoodi karo oo aan ku dari karno steroids, ogsijiin iyo daryeel taageero dhow oo aan horeyba u bixinay mashaariicdayada. Sida daawayn cusub ay soo baxayaan, waxa ay noqon doontaa si fudud bini’aadantinimada ka baxsan haddii aan laga heli karin goobaha kheyraadka ku xaddidan, sababtoo ah waa sharciyeysneed oo aad qaali u ah.
WHO waxa ay ku dartay waxa ay sheegtay in ay yihiin “naf-badbaadiyeyaal” interleukin-6 reseptors blockers liiska daawaynta COVID-19 ee bishii July ee la soo dhaafay. Waxay ku talisay isticmaalka corticosteroids Sebtembar 2020.
Toddobaadyadii la soo dhaafay, maamulayaasha dawladdu waxay sidoo kale oggolaadeen daawaynta afka ee cusub ee cudurka, oo ay ku jiraan Paxlovid, Pfizer’s pill kiniiniga, kaas oo muujiyay ku dhawaad boqolkiiba 90 waxtarka ka hortagga seexinta cusbitaalka iyo dhimashada bukaannada khatarta sare leh. Waxay sidoo kale ku sii haysataa waxtarkeeda Omicron, shirkaddu waxay tidhi.
XIGASHO: AL JAZEERA